Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,101.9
9.8 (0.32%)

 

  • STI Straits Times Index
    3,101.9
    9.8 (0.32%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,501.7
    4.8 (0.32%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,766.7
    -22.2 (-0.09%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,607.4
    33.6 (0.94%)
    Index delayed 15 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 818.5M
  • Value: 1,115.1M
  • Rise: 182
  • Fall: 131
  • Unch: 448

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.083-
Genting Sing0.760+0.015
SingHaiyi0.117-
CapLand IntCom T2.060-0.010
Singtel2.380-
Metal Component0.047-0.003
HGH0.019-
Golden Agri-Res0.235+0.010
HPH Trust USD0.230+0.005
Mapletree Log Tr1.870-

World Indices

World Indices
Name Last Change
Nasdaq 15,537.7 -245.1
HSI 23,766.7 -22.2
HSCEI 8,455.5 -50.9
Jakarta 6,538.5 -45.3
Nikkei 225 27,935.6
SSE Comp 3,607.4 +33.6
Shanghai A 3,781.0 +35.2
Shanghai B 286.0 +2.9
KOSPI 2,968.3 +23.1

Nikkei 225 updated at end-of-day. Other Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 REDHILL BIOPHARMA LTD. SPONSORED ADR
Updated on 02 Dec 2021 (End of trading day)
Last (USD): 2.740 Change: +0.020 High: 2.940 Remarks: -
Change (%): +0.74 Low: 2.660

Company Background

RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. It operates through the following segments: Commercial Operations and the Research & Development. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company’s subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Click to show Stock Prices chart

Key Statistics

EPS (USD) a -1.45364 Trailing EPS (USD) b -1.45388 NAV (USD) c 0.5645
PE a - Trailing PE d - Price / NAV c 4.8539
Dividend Yield (%) e - Cash In Hand (USD) f 0.9888 Issued & Paid-up Shares g 52,401,600
Piotroski F Score 1 Market Cap (M) 143.580 Free Float (%) 87.8
Return on Equity (ROE) (%) h n.a. Revenue Growth (%) TTM i 91.320
Net Earnings Growth (%) j -53.735 Net Debt/Equity k n.a.
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 29 Nov 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.260
-8.67 %
10 Days --0.090
-3.18 %
20 Days --2.330
-45.96 %
Medium Term Return 3 Months --6.750
-71.13 %
6 Months --4.330
-61.24 %
1 Year --6.080
-68.93 %
Long Term Return 2 Years --3.840
-58.36 %
3 Years --4.310
-61.13 %
5 Years --8.590
-75.82 %
Annualised Return Annualised --
-24.72 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 NASDAQ 143.580 - - 4.8539 -
Industry Pharmaceuticals: Major NASDAQ 2,115.390 83.887 91.614 2.6899 0.028
Local Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 169,756.953 53.115 115.402 4.2712 -
Local Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 120,515.015 8.585 17.403 1.6070 -
Local Peer ROYALTY PHARMA PLC NASDAQ 23,606.925 24.211 30.156 4.0750 0.493
Local Peer REPLIGEN CORP NASDAQ 14,862.655 248.016 125.023 8.6649 -
Local Peer VIATRIS INC NASDAQ 14,754.558 - - 0.6979 -
Local Peer CUREVAC NV NASDAQ 8,211.135 - - - -
Local Peer ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 8,297.888 - - 7.2062 -
Local Peer EVOTEC SE SPON ADS EACH REP 0.50 ORD SHS NASDAQ 8,104.034 1,136.811 27.510 7.0442 -
Local Peer LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS NASDAQ 7,041.783 - - 31.1763 -
Local Peer HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS NASDAQ 5,688.147 - - 5.7760 -
Local Peer I MAB SPON ADS EACH REP 2.3 ORD SHS NASDAQ 4,482.279 65.697 65.697 5.2093 -
Local Peer CEREVEL THERAPEUTICS HLDGS INC NASDAQ 4,833.758 - - 7.6838 -
Other Local Peers ALLAKOS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), OPKO HEALTH INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), ERASCA INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), GH RESEARCH PLC (NASDAQ), PROCAPS GROUP S.A. (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), GENERATION BIO CO (NASDAQ), ICOSAVAX INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), KRONOS BIO INC (NASDAQ), ANNEXON INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), 2SEVENTY BIO INC (NASDAQ), PETIQ INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), VERU INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), PHARVARIS NV (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), PROVENTION BIO INC (NASDAQ), XILIO THERAPEUTICS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), AC IMMUNE SA (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), COMPASS THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), CLENE INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), IMMUNIC INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), DURECT CORP (NASDAQ), VINCERX PHARMA INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), BEYONDSPRING INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), ATHENEX INC (NASDAQ), OBSEVA SA (NASDAQ), INOZYME PHARMA INC (NASDAQ), MUSTANG BIO INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), NEXIMMUNE INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), ALZAMEND NEURO INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), POLYPID LTD (NASDAQ), JOURNEY MEDICAL CORPORATION (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), EYENOVIA INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), ENTERA BIO LTD (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), NOVAN INC (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), IMARA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), EDESA BIOTECH INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), MANNATECH INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), GENPREX INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), GALECTO INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), RENOVORX INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ),